Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C

Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Kwan Soo Byun, Seung Woon Paik, Young Suk Lim, Han Chu Lee, KwangHyub Han, Kwan Sik Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginterferon α-2a and ribavirin dose modifications and their effect on the virologic response in Koreans. Methods: Patients with detectable HCV RNA and enrolled from multicenters were treated with peginterferon α-2a (180 μg/week) and ribavirin (800 mg/day) for 24 weeks (genotype non-1, n=37) or peginterferon α-2a (180 μg/ week) and ribavirin (1,000-1,200 mg/day) for 48 weeks (genotype 1, n=55). Results: Early virologic response (EVR) and sustained virologic response (SVR) were 77.2% (genotype 1, 75%; non-1, 81%) and 66.3% (genotype 1, 56%; non-1, 81%), respectively. The frequency of dose modification was 32.6% within the first 12 weeks and 52.2% during the entire treatment period. No difference was found in SVR regardless of dose modification. However, the SVR for patients using ≥80% of the peginterferon dose was significantly higher than for those using <80% (81.3 vs. 50.0%, p=0.007), despite varying ribavirin doses. No difference was found in SVR regardless of whether the ribavirin dose was <80% or not. These results did not change based on genotype. Conclusions: We suggest that using at least 80% of the peginterferon α-2a dose in Koreans not only maintains SVR but also reduces drug side effects during the entire treatment period. A lower dose of ribavirin may be as efficacious as a standard dose.

Original languageEnglish
Pages (from-to)203-211
Number of pages9
JournalKorean Journal of Internal Medicine
Volume24
Issue number3
DOIs
Publication statusPublished - 2009 Dec 21

Fingerprint

Ribavirin
Chronic Hepatitis C
Genotype
Drug-Related Side Effects and Adverse Reactions
peginterferon alfa-2a
Therapeutics
Sustained Virologic Response
RNA

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Kwon, Jung Hyun ; Bae, Si Hyun ; Choi, Jong Young ; Yoon, Seung Kew ; Byun, Kwan Soo ; Paik, Seung Woon ; Lim, Young Suk ; Lee, Han Chu ; Han, KwangHyub ; Lee, Kwan Sik. / Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. In: Korean Journal of Internal Medicine. 2009 ; Vol. 24, No. 3. pp. 203-211.
@article{efcf02a8823f4e508eeae8e143d2f523,
title = "Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C",
abstract = "Background/Aims: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginterferon α-2a and ribavirin dose modifications and their effect on the virologic response in Koreans. Methods: Patients with detectable HCV RNA and enrolled from multicenters were treated with peginterferon α-2a (180 μg/week) and ribavirin (800 mg/day) for 24 weeks (genotype non-1, n=37) or peginterferon α-2a (180 μg/ week) and ribavirin (1,000-1,200 mg/day) for 48 weeks (genotype 1, n=55). Results: Early virologic response (EVR) and sustained virologic response (SVR) were 77.2{\%} (genotype 1, 75{\%}; non-1, 81{\%}) and 66.3{\%} (genotype 1, 56{\%}; non-1, 81{\%}), respectively. The frequency of dose modification was 32.6{\%} within the first 12 weeks and 52.2{\%} during the entire treatment period. No difference was found in SVR regardless of dose modification. However, the SVR for patients using ≥80{\%} of the peginterferon dose was significantly higher than for those using <80{\%} (81.3 vs. 50.0{\%}, p=0.007), despite varying ribavirin doses. No difference was found in SVR regardless of whether the ribavirin dose was <80{\%} or not. These results did not change based on genotype. Conclusions: We suggest that using at least 80{\%} of the peginterferon α-2a dose in Koreans not only maintains SVR but also reduces drug side effects during the entire treatment period. A lower dose of ribavirin may be as efficacious as a standard dose.",
author = "Kwon, {Jung Hyun} and Bae, {Si Hyun} and Choi, {Jong Young} and Yoon, {Seung Kew} and Byun, {Kwan Soo} and Paik, {Seung Woon} and Lim, {Young Suk} and Lee, {Han Chu} and KwangHyub Han and Lee, {Kwan Sik}",
year = "2009",
month = "12",
day = "21",
doi = "10.3904/kjim.2009.24.3.203",
language = "English",
volume = "24",
pages = "203--211",
journal = "Korean Journal of Internal Medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "3",

}

Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. / Kwon, Jung Hyun; Bae, Si Hyun; Choi, Jong Young; Yoon, Seung Kew; Byun, Kwan Soo; Paik, Seung Woon; Lim, Young Suk; Lee, Han Chu; Han, KwangHyub; Lee, Kwan Sik.

In: Korean Journal of Internal Medicine, Vol. 24, No. 3, 21.12.2009, p. 203-211.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C

AU - Kwon, Jung Hyun

AU - Bae, Si Hyun

AU - Choi, Jong Young

AU - Yoon, Seung Kew

AU - Byun, Kwan Soo

AU - Paik, Seung Woon

AU - Lim, Young Suk

AU - Lee, Han Chu

AU - Han, KwangHyub

AU - Lee, Kwan Sik

PY - 2009/12/21

Y1 - 2009/12/21

N2 - Background/Aims: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginterferon α-2a and ribavirin dose modifications and their effect on the virologic response in Koreans. Methods: Patients with detectable HCV RNA and enrolled from multicenters were treated with peginterferon α-2a (180 μg/week) and ribavirin (800 mg/day) for 24 weeks (genotype non-1, n=37) or peginterferon α-2a (180 μg/ week) and ribavirin (1,000-1,200 mg/day) for 48 weeks (genotype 1, n=55). Results: Early virologic response (EVR) and sustained virologic response (SVR) were 77.2% (genotype 1, 75%; non-1, 81%) and 66.3% (genotype 1, 56%; non-1, 81%), respectively. The frequency of dose modification was 32.6% within the first 12 weeks and 52.2% during the entire treatment period. No difference was found in SVR regardless of dose modification. However, the SVR for patients using ≥80% of the peginterferon dose was significantly higher than for those using <80% (81.3 vs. 50.0%, p=0.007), despite varying ribavirin doses. No difference was found in SVR regardless of whether the ribavirin dose was <80% or not. These results did not change based on genotype. Conclusions: We suggest that using at least 80% of the peginterferon α-2a dose in Koreans not only maintains SVR but also reduces drug side effects during the entire treatment period. A lower dose of ribavirin may be as efficacious as a standard dose.

AB - Background/Aims: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginterferon α-2a and ribavirin dose modifications and their effect on the virologic response in Koreans. Methods: Patients with detectable HCV RNA and enrolled from multicenters were treated with peginterferon α-2a (180 μg/week) and ribavirin (800 mg/day) for 24 weeks (genotype non-1, n=37) or peginterferon α-2a (180 μg/ week) and ribavirin (1,000-1,200 mg/day) for 48 weeks (genotype 1, n=55). Results: Early virologic response (EVR) and sustained virologic response (SVR) were 77.2% (genotype 1, 75%; non-1, 81%) and 66.3% (genotype 1, 56%; non-1, 81%), respectively. The frequency of dose modification was 32.6% within the first 12 weeks and 52.2% during the entire treatment period. No difference was found in SVR regardless of dose modification. However, the SVR for patients using ≥80% of the peginterferon dose was significantly higher than for those using <80% (81.3 vs. 50.0%, p=0.007), despite varying ribavirin doses. No difference was found in SVR regardless of whether the ribavirin dose was <80% or not. These results did not change based on genotype. Conclusions: We suggest that using at least 80% of the peginterferon α-2a dose in Koreans not only maintains SVR but also reduces drug side effects during the entire treatment period. A lower dose of ribavirin may be as efficacious as a standard dose.

UR - http://www.scopus.com/inward/record.url?scp=70449711352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449711352&partnerID=8YFLogxK

U2 - 10.3904/kjim.2009.24.3.203

DO - 10.3904/kjim.2009.24.3.203

M3 - Article

VL - 24

SP - 203

EP - 211

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 1226-3303

IS - 3

ER -